Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (SE:IMMNOV)
:IMMNOV
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.19Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial, scientific and reimbursement progress: a successful product launch, strong clinical publications and podium presence, an awarded Medicare pricing of USD 897, state approvals in 48 states, targeted hiring of account managers, and a completed rights issue that improved cash position. However, near-term revenue remains limited, full payer coverage is not yet granted, cash runway extends only to Q3 2026 without additional capital, and realized per-test pricing and collections are still uncertain. The company emphasized disciplined spending, planned clinical utility data collection (including a 400-patient registry) and a mid-2026 Medicare submission with rolling data updates to mitigate coverage risk.Company Guidance
Commercial Launch of PancreaSure
PancreaSure commercially launched in September 2025 with initial adoption at high-risk surveillance centers; 6 centers regularly using the test at year-end and 4 new centers added in Q4. UC Health >100 tests performed; strong order activity reported at Northwestern Medicine and HonorHealth.
Attractive Medicare Pricing Secured
Secured a Medicare reimbursement rate of USD 897 and an appropriate billing code, positioning the company for substantial per-test reimbursement once coverage decisions are granted.
Strong Scientific and Clinical Dissemination
Five clinical studies published in scientific journals, PancreaSure data selected for podium presentations at five meetings, and the CLARITI study named best of DDW, demonstrating robust scientific validation and visibility.
Progress on Regulatory State Approvals
Laboratory/service approvals in 48 of 50 U.S. states (96%); California approval received in January 2026 and New York approval pending (inspection completed with 4 minor findings already addressed).
Funding and Improved Cost Discipline
Completed a rights issue of SEK 100 million (88% subscribed by existing shareholders) delivering a net cash injection of SEK 69.8 million; earlier fundraising referenced of over SEK 140 million to support launch and studies. Achieved reduced operating losses and lower cash burn via R&D cost reductions and cost discipline.
Operational and Commercial Team Build-Out
Hired 3 strategic account managers with industry experience (Exact Sciences, Quest, Myriad) to expand outreach, accelerate pipeline conversion, integrate the test into center protocols, and deepen relationships across surveillance center teams.
Clinical and Reimbursement Strategy Underway
Three clinical validation studies completed (two published with AFFIRM pending publication), two clinical utility studies underway, and a planned registry targeting ~400 patients in 2026; plan to submit for Medicare coverage mid-2026 with rolling data updates.
Financial Efficiency Improvements
Q4 operating loss narrowed to SEK 16.4 million from SEK 30.1 million year-over-year (approximate reduction of 45.5%), and cash burn in Q4 was SEK 6.6 million/month, below prior guidance of SEK 8–10 million/month (17.5%–34% lower).
SE:IMMNOV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:IMMNOV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | kr0.20 | kr0.17 | -13.33% |
Nov 26, 2025 | kr0.26 | kr0.28 | +7.81% |
Aug 28, 2025 | kr0.70 | kr0.51 | -26.47% |
May 14, 2025 | kr0.31 | kr0.30 | -5.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immunovia AB (SE:IMMNOV) report earnings?
Immunovia AB (SE:IMMNOV) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Immunovia AB (SE:IMMNOV) earnings time?
Immunovia AB (SE:IMMNOV) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Immunovia AB stock?
The P/E ratio of Immunovia AB is N/A.
What is SE:IMMNOV EPS forecast?
Currently, no data Available